Who
Elaine Jones V
Director
Company insider
Files Form 4 as: Director, NextCure; Director, CytomX Therapeutics; Director, Gritstone bio; Director, Synlogic; Director and Other, Gyre Therapeutics.
In numbers
- Trades disclosed
- 62
- Buys
- 1
- Sells
- 0
- Bought
- $7,750
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 18 Apr 2006
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —51,800 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —51,800 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —19,000 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —19,000 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —12,500 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —15,942 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —51,800 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,250 at $0.00 | filing |
| 16 Jun 2023filed 21 Jun 2023 | Gritstone biooption or derivative | SEC FORM 4 Code A | —51,800 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 29 Mar 2023filed 31 Mar 2023 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,7505,000 at $1.55 | filing |
| 23 Jun 2022filed 24 Jun 2022 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,250 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.